Geoffrey Fatti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Geoffrey Fatti has a total of 555 co-authors. Here are the top co-authors by number of shared publications:
Ashraf Grimwood
Kheth'Impilo AIDS Free Living, Cape Town, South Africa
23 shared publicationsBrian Eley
Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa
10 shared publicationsNajma Shaikh
Kheth'Impilo AIDS Free Living, Cape Town, South Africa
8 shared publications- Peter Bock
Affiliation Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa
8 shared publications - Frank Tanser
South African Centre for Epidemiological Modelling and Analysis, Centre for Epidemic Response and Innovation, School for Data Science and Computational Thinking, Stellenbosch University, South Africa
7 shared publications - Andrew Boulle
Centre for Integrated Data and Epidemiological Research, School of Public Health, University of Cape Town, South Africa
5 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0360657
Evaluating long-term programmatic outcomes of patients with advanced HIV disease: Insights from 12 years of antiretroviral therapy scale-up in rural KwaZulu-Natal
Background: Advanced HIV disease (AHD) remains a significant public health challenge, despite the widespread scale-up of antiretroviral therapy (ART) in South Africa. Understanding long-term treatment outcomes among patients with AHD under routine programmatic conditions is critical. However, there is a paucity of longitudinal data on clinical outcomes in this population, particularly within high-HIV prevalence rural settings. This study evaluated retention in care and virological outcomes among patients initiating ART with AHD in rural KwaZulu-Natal between 2008 and 2020. Methods: We conducted a retrospective cohort study using routine data from 10 public health facilities. Adults (≥18 years) with CD4 < 200 cells/μL or WHO stage 3/4 who initiated ART between January 1, 2008, and December 31, 2020, were included. Primary outcomes were retention in care at 6, 12, 24, 36, and 48 months. Secondary outcomes included viral load (VL) completion and suppression (<1000 copies/μL). Competing risk regression and Poisson regression models were used to identify factors associated with loss to follow-up (LTFU) and virological suppression. Results: Of 40,432 individuals who initiated ART between 2008 and 2020, 9,608 met the criteria for AHD. Retention in care was 98%, 94%, 89%, and 85% at 12, 24, 36, and 48 months, respectively. Men (adjusted subdistribution hazard ratio [aSHR]: 1.35; 95% confidence interval [CI]: 1.23–1.47) and individuals with CD4 counts <100 cells/µL (aSHR: 1.13; 95% CI: 1.08–1.26) had a higher risk of loss to follow-up. Although viral load (VL) completion declined over time (49.3% at 6 months to 31.5% at 48 months), suppression remained above 83% among those with available VL data. Undetectable VL increased from 25.5% to 33.0% between 12 and 48 months. Patients initiating ART during the Universal Test and Treat (UTT) era (2016–2020) had higher retention (78.8%) than those treated between 2012–2015 (62.8%) and higher viral load (VL) suppression (risk ratio [RR]: 1.13; 95% CI: 1.01–1.28) compared with the 2008–2011 cohort. Women (RR 1.18; 95% CI: 1.11–1.25) and those initiating ART within 7 days (RR 1.30; 95% CI: 1.04–1.38) were more likely to achieve virological suppression at any time point. Conclusion: This study demonstrates high retention and virological suppression rates among patients with AHD in rural South Africa, particularly under the UTT strategy. Despite these successes, VL testing uptake remains suboptimal, and a considerable gap persists in achieving undetectable VL levels. Integrating the WHO AHD care package and prioritizing early ART initiation and male-focused interventions may further improve outcomes and support efforts to end the HIV epidemic.
- 27 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0360657
Open AccessEvaluating long-term programmatic outcomes of patients with advanced HIV disease: Insights from 12 years of antiretroviral therapy scale-up in rural KwaZulu-Natal
Background: Advanced HIV disease (AHD) remains a significant public health challenge, despite the widespread scale-up of antiretroviral therapy (ART) in South Africa. Understanding long-term treatment outcomes among patients with AHD under routine programmatic conditions is critical. However, there is a paucity of longitudinal data on clinical outcomes in this population, particularly within high-HIV prevalence rural settings. This study evaluated retention in care and virological outcomes among patients initiating ART with AHD in rural KwaZulu-Natal between 2008 and 2020. Methods: We conducted a retrospective cohort study using routine data from 10 public health facilities. Adults (≥18 years) with CD4 < 200 cells/μL or WHO stage 3/4 who initiated ART between January 1, 2008, and December 31, 2020, were included. Primary outcomes were retention in care at 6, 12, 24, 36, and 48 months. Secondary outcomes included viral load (VL) completion and suppression (<1000 copies/μL). Competing risk regression and Poisson regression models were used to identify factors associated with loss to follow-up (LTFU) and virological suppression. Results: Of 40,432 individuals who initiated ART between 2008 and 2020, 9,608 met the criteria for AHD. Retention in care was 98%, 94%, 89%, and 85% at 12, 24, 36, and 48 months, respectively. Men (adjusted subdistribution hazard ratio [aSHR]: 1.35; 95% confidence interval [CI]: 1.23–1.47) and individuals with CD4 counts <100 cells/µL (aSHR: 1.13; 95% CI: 1.08–1.26) had a higher risk of loss to follow-up. Although viral load (VL) completion declined over time (49.3% at 6 months to 31.5% at 48 months), suppression remained above 83% among those with available VL data. Undetectable VL increased from 25.5% to 33.0% between 12 and 48 months. Patients initiating ART during the Universal Test and Treat (UTT) era (2016–2020) had higher retention (78.8%) than those treated between 2012–2015 (62.8%) and higher viral load (VL) suppression (risk ratio [RR]: 1.13; 95% CI: 1.01–1.28) compared with the 2008–2011 cohort. Women (RR 1.18; 95% CI: 1.11–1.25) and those initiating ART within 7 days (RR 1.30; 95% CI: 1.04–1.38) were more likely to achieve virological suppression at any time point. Conclusion: This study demonstrates high retention and virological suppression rates among patients with AHD in rural South Africa, particularly under the UTT strategy. Despite these successes, VL testing uptake remains suboptimal, and a considerable gap persists in achieving undetectable VL levels. Integrating the WHO AHD care package and prioritizing early ART initiation and male-focused interventions may further improve outcomes and support efforts to end the HIV epidemic.
- Open Access
- 13 June 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (8)
Laboratory test availability and user fees in routine HIV care: a global analysis in 42 countries
Background: Laboratory testing is critical for diagnosis and treatment management for people with HIV, but is costly. When HIV resources are constrained, even before recent disruptions in US funding for the global HIV response, user fees have been used for cost recovery. We describe availability and charging of user fees for routine HIV laboratory testing globally. Methods: Routine test availability and charging of user fees were examined via an HIV clinic survey conducted September 2020–March 2021; responses reflected clinical practices in 2019. HIV clinics came from 42 low-, middle-, and high-income countries from the International epidemiology Databases to Evaluate AIDS (IeDEA) global research consortium. Results: Across 199 clinics, on-site test availability was generally limited, reflecting constraints in routine test availability across health conditions more broadly. Over 90% of clinics did not report charging of user fees. A higher percentage reporting user fees were from middle-income countries and from countries receiving Global Fund or PEPFAR country support, which may reflect settings with ongoing health funding gaps. Conclusions: Availability and user fees for essential HIV-related laboratory tests were limited in 2019. Monitoring user fees may provide insights about how national health systems are responding to steep reductions in global donor funding.
- 13 June 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (8)
Open AccessLaboratory test availability and user fees in routine HIV care: a global analysis in 42 countries
Background: Laboratory testing is critical for diagnosis and treatment management for people with HIV, but is costly. When HIV resources are constrained, even before recent disruptions in US funding for the global HIV response, user fees have been used for cost recovery. We describe availability and charging of user fees for routine HIV laboratory testing globally. Methods: Routine test availability and charging of user fees were examined via an HIV clinic survey conducted September 2020–March 2021; responses reflected clinical practices in 2019. HIV clinics came from 42 low-, middle-, and high-income countries from the International epidemiology Databases to Evaluate AIDS (IeDEA) global research consortium. Results: Across 199 clinics, on-site test availability was generally limited, reflecting constraints in routine test availability across health conditions more broadly. Over 90% of clinics did not report charging of user fees. A higher percentage reporting user fees were from middle-income countries and from countries receiving Global Fund or PEPFAR country support, which may reflect settings with ongoing health funding gaps. Conclusions: Availability and user fees for essential HIV-related laboratory tests were limited in 2019. Monitoring user fees may provide insights about how national health systems are responding to steep reductions in global donor funding.
- Open Access
- 9 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0339469
Feasibility and testing outcomes of task-shared implementation of advanced HIV disease point of care tests in Beira (Mozambique) and Kinshasa (DRC)
Introduction: Mortality from advanced HIV disease (AHD) remains high and current strategies to promptly test people eligible for AHD screening, are insufficient. Task sharing for point of care (POC) testing utilizing lay health workers (LHW) is recommended, however it is marginally practised in many countries. This study sought to describe the feasibility and testing outcomes of task-shared implementation of the AHD POC diagnostic tests utilizing LHW and professional health care workers (HCW). Methods: This was a cross-sectional mixed-methods implementation study in seven primary and three secondary health facilities, in Mozambique and Democratic Republic of Congo (DRC). From March to November 2022, consenting HIV positive adults eligible for AHD screening, were offered Visitect CD4 lateral flow assay (LFA), and or subsequently urinary Mycobacterium tuberculosis lipoarabinomannan antigen (TB LAM) and cryptococcal antigen (CrAg) tests. The primary study outcome was the proportion of testers (LHW and HCW) who found it ‘easy’ to integrate the 3 POC tests within their routine work together with their opinions on the value of task shared AHD POC testing. Results: A total of 1542 patients were screened for AHD by 35 LHW (34 counsellors, and 1 lay educator) and 45 professional HCW (28 nurses and 9 clinical officers and 8 doctors). In the study period, LHW conducted a median number of 27 [IQR: 16–34] Visitect CD4 LFA tests, whereas nurses, clinical officers together with doctors conducted 19 and 11 respectively. Visitect CD4 LFA increased CD4 testing by 10.7% in Munhava (Beira) and 22.9% in CHK (DRC), complementing existing CD4 testing instruments. Among testers who completed the feasibility survey, nearly sixty percent of testers (25/42; LHW in particular) found it easy to integrate AHD POC testing within their routine workflow. The prevalence of AHD was 39.2% (604/1542). A total of 34% (146/430) and 5.4% (22/407) of patients tested positive for urine TB LAM and plasma CrAg respectively. Of these, 82.2% (120/146) and 36.4% (8/22) had a documented therapeutic intervention. The median time for completing the Visitect CD4 LFA and conveying the results to the clinician was 59 minutes [IQR: 48–71]. Conclusion: Task-shared integrated testing for AHD at POC among LHW and professional HCW, is feasible and can improve access to AHD testing. However, as POC testing responsibilities become shared, documentation of testing activities could increase in complexity and can be easily fragmented, especially when there is limited supervision. Nevertheless, LHW are well suited for POC testing due to limited availability and higher clinical workload of other HCW.
- 9 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0339469
Open AccessFeasibility and testing outcomes of task-shared implementation of advanced HIV disease point of care tests in Beira (Mozambique) and Kinshasa (DRC)
Introduction: Mortality from advanced HIV disease (AHD) remains high and current strategies to promptly test people eligible for AHD screening, are insufficient. Task sharing for point of care (POC) testing utilizing lay health workers (LHW) is recommended, however it is marginally practised in many countries. This study sought to describe the feasibility and testing outcomes of task-shared implementation of the AHD POC diagnostic tests utilizing LHW and professional health care workers (HCW). Methods: This was a cross-sectional mixed-methods implementation study in seven primary and three secondary health facilities, in Mozambique and Democratic Republic of Congo (DRC). From March to November 2022, consenting HIV positive adults eligible for AHD screening, were offered Visitect CD4 lateral flow assay (LFA), and or subsequently urinary Mycobacterium tuberculosis lipoarabinomannan antigen (TB LAM) and cryptococcal antigen (CrAg) tests. The primary study outcome was the proportion of testers (LHW and HCW) who found it ‘easy’ to integrate the 3 POC tests within their routine work together with their opinions on the value of task shared AHD POC testing. Results: A total of 1542 patients were screened for AHD by 35 LHW (34 counsellors, and 1 lay educator) and 45 professional HCW (28 nurses and 9 clinical officers and 8 doctors). In the study period, LHW conducted a median number of 27 [IQR: 16–34] Visitect CD4 LFA tests, whereas nurses, clinical officers together with doctors conducted 19 and 11 respectively. Visitect CD4 LFA increased CD4 testing by 10.7% in Munhava (Beira) and 22.9% in CHK (DRC), complementing existing CD4 testing instruments. Among testers who completed the feasibility survey, nearly sixty percent of testers (25/42; LHW in particular) found it easy to integrate AHD POC testing within their routine workflow. The prevalence of AHD was 39.2% (604/1542). A total of 34% (146/430) and 5.4% (22/407) of patients tested positive for urine TB LAM and plasma CrAg respectively. Of these, 82.2% (120/146) and 36.4% (8/22) had a documented therapeutic intervention. The median time for completing the Visitect CD4 LFA and conveying the results to the clinician was 59 minutes [IQR: 48–71]. Conclusion: Task-shared integrated testing for AHD at POC among LHW and professional HCW, is feasible and can improve access to AHD testing. However, as POC testing responsibilities become shared, documentation of testing activities could increase in complexity and can be easily fragmented, especially when there is limited supervision. Nevertheless, LHW are well suited for POC testing due to limited availability and higher clinical workload of other HCW.
- 18 July 2025
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 68 (1) , e17-e23
Effectiveness of Behavioral Interventions for Managing Occupational Exposure to Sharps and Body Fluids Among Health Care Workers
Objective: The aim of the study was to evaluate the impact of behavioral change interventions on health care workers’ knowledge, attitudes, and practices related to blood-borne pathogen exposure in Ethiopian hospitals. Methods: A controlled pre/post cross-sectional study was conducted in four hospitals using structured questionnaires. Interventions included training and capacity-building, guided by the health belief model and social cognitive theory. Results: Composite scores for knowledge and practices increased significantly. Knowledge rose from 914 to 1226 ( P = 0.03), with marked improvements in risk perception (31%–80%, P < 0.001) and understanding postexposure policy (44%–73%, P < 0.001). Safety practices increased from 990 to 1409 ( P = 0.05). Exposure reporting rose from 22% to 72% ( P < 0.001), and use of the prevention guide from 55% to 89% ( P < 0.001). Conclusions: Behavioral interventions enhanced knowledge and exposure management practices.
- 18 July 2025
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 68 (1) , e17-e23
Effectiveness of Behavioral Interventions for Managing Occupational Exposure to Sharps and Body Fluids Among Health Care Workers
Objective: The aim of the study was to evaluate the impact of behavioral change interventions on health care workers’ knowledge, attitudes, and practices related to blood-borne pathogen exposure in Ethiopian hospitals. Methods: A controlled pre/post cross-sectional study was conducted in four hospitals using structured questionnaires. Interventions included training and capacity-building, guided by the health belief model and social cognitive theory. Results: Composite scores for knowledge and practices increased significantly. Knowledge rose from 914 to 1226 ( P = 0.03), with marked improvements in risk perception (31%–80%, P < 0.001) and understanding postexposure policy (44%–73%, P < 0.001). Safety practices increased from 990 to 1409 ( P = 0.05). Exposure reporting rose from 22% to 72% ( P < 0.001), and use of the prevention guide from 55% to 89% ( P < 0.001). Conclusions: Behavioral interventions enhanced knowledge and exposure management practices.
- Open Access
- 7 July 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (S3) , e26477
Scale of differentiated service delivery implementation in HIV care facilities in low‐ and middle‐income countries: a global facility survey
Introduction: In 2016, the World Health Organization recommended differentiated service delivery (DSD) as a client‐centred approach to simplify HIV care in frequency and intensity, thus reducing the clinic visit burden on individuals and HIV programmes. We describe the scale of DSD implementation among HIV facilities in low‐ and middle‐income countries (LMICs) in Latin America, Africa and the Asia‐Pacific before the COVID‐19 pandemic.Methods: We analysed facility‐level survey data from HIV care facilities participating in the International epidemiology Databases to Evaluate AIDS consortium in 2019. We used descriptive statistics to summarise the availability of DSD, multi‐month dispensing (MMD) and DSD for HIV treatment models. We explored factors associated with DSD implementation using multivariable models.Results: We included 175 facilities in the Asia‐Pacific (n = 30), Latin America (n = 8), Central Africa (n = 21), East Africa (n = 74), Southern Africa (n = 28) and West Africa (n = 14). Overall, 133 facilities (76%) reported implementing DSD. Of these, 91% offered DSD for HIV treatment, 61% for HIV testing and 59% for antiretroviral therapy (ART) initiation. The most common duration of ART refills for clinically stable clients was 3MMD, (70%), followed by monthly (14%) and 6MMD (10%). Facility‐based individual models were the most frequently available DSD for the HIV treatment model (82%), followed by client‐managed group models (60%). Out‐of‐facility individual models were available at 48% of facilities. Facility‐based individual models were particularly common among facilities in East (92%) and Southern Africa (96%). Facilities in medium and high HIV prevalence countries, and those with 3MMD, were more likely to implement DSD.Conclusions: In 2019, DSD was available in most HIV care facilities globally but was not evenly implemented across regions and HIV services. Most offered facility‐based DSD for HIV treatment models and 3MMD for clinically stable clients. Efforts to expand DSD for HIV testing and ART initiation and to offer longer MMD can improve long‐term retention in care of people living with HIV in LMICs, while further alleviating the operational burden on healthcare services. These findings from the pre‐COVID‐19 era underline the need for strengthening DSD in HIV care, which remains at the centre of current efforts towards client‐centred care.
- 7 July 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (S3) , e26477
Open AccessScale of differentiated service delivery implementation in HIV care facilities in low‐ and middle‐income countries: a global facility survey
Introduction: In 2016, the World Health Organization recommended differentiated service delivery (DSD) as a client‐centred approach to simplify HIV care in frequency and intensity, thus reducing the clinic visit burden on individuals and HIV programmes. We describe the scale of DSD implementation among HIV facilities in low‐ and middle‐income countries (LMICs) in Latin America, Africa and the Asia‐Pacific before the COVID‐19 pandemic.Methods: We analysed facility‐level survey data from HIV care facilities participating in the International epidemiology Databases to Evaluate AIDS consortium in 2019. We used descriptive statistics to summarise the availability of DSD, multi‐month dispensing (MMD) and DSD for HIV treatment models. We explored factors associated with DSD implementation using multivariable models.Results: We included 175 facilities in the Asia‐Pacific (n = 30), Latin America (n = 8), Central Africa (n = 21), East Africa (n = 74), Southern Africa (n = 28) and West Africa (n = 14). Overall, 133 facilities (76%) reported implementing DSD. Of these, 91% offered DSD for HIV treatment, 61% for HIV testing and 59% for antiretroviral therapy (ART) initiation. The most common duration of ART refills for clinically stable clients was 3MMD, (70%), followed by monthly (14%) and 6MMD (10%). Facility‐based individual models were the most frequently available DSD for the HIV treatment model (82%), followed by client‐managed group models (60%). Out‐of‐facility individual models were available at 48% of facilities. Facility‐based individual models were particularly common among facilities in East (92%) and Southern Africa (96%). Facilities in medium and high HIV prevalence countries, and those with 3MMD, were more likely to implement DSD.Conclusions: In 2019, DSD was available in most HIV care facilities globally but was not evenly implemented across regions and HIV services. Most offered facility‐based DSD for HIV treatment models and 3MMD for clinically stable clients. Efforts to expand DSD for HIV testing and ART initiation and to offer longer MMD can improve long‐term retention in care of people living with HIV in LMICs, while further alleviating the operational burden on healthcare services. These findings from the pre‐COVID‐19 era underline the need for strengthening DSD in HIV care, which remains at the centre of current efforts towards client‐centred care.
- Open Access
- 18 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0317674
Persistent advanced HIV disease in rural KwaZulu-Natal, South Africa: Trends, characteristics, and the urgent need for targeted interventions
Background: Advanced HIV disease (AHD) remains a persistent public health challenge. Data regarding the burden, characteristics and predictors of AHD is scarce specifically for rural settings of sub-Saharan Africa. This study aimed to describe trends in annual CD4 count distribution and to characterise adult persons living with HIV (PLWH) on ART who have AHD in rural KwaZulu-Natal, South Africa. Methods: A retrospective cohort design of annual CD4 count distribution was conducted among antiretroviral therapy (ART) patients aged 18 years and older. We used routinely collected data from adults receiving ART in Eshowe and Mbongolwane areas in KwaZulu-Natal, South Africa, between January 1, 2008, and June 30, 2021. Fine-Greys competing risks regression with proportional sub-distribution hazard models was used to determine factors associated with time to CD4 recovery. Results: A total of 34,729 patients were included of which 68.5% were females. The median age of the study sample was 33.5 years (interquartile range [IQR] 27–41 years), and the median CD4 count was 277 cells/μL (IQR, 149–452 cells/μL). The proportion of patients entering care with AHD declined over time from 62% in 2008 to 20% in 2021. Across all periods, those entering care with AHD were more likely to be men when compared to women (Relative risk [RR] 1.49; 95% 1.33–1.67). In addition, the proportion of patients with AHD who were ART-experienced increased from 4% in 2008 to 63% in 2021. Among ART-experienced, men were more likely to present with AHD compared to women (RR 1.79; 95% CI 1.52–2.11). Among those with AHD, the cumulative incidence of CD4 recovery to > 350 cells/μL was 3.21 (95% CI 3.13–3.29) per 100 adult-years follow-up time. Conclusion: Over time fewer patients with AHD are entering care in KwaZulu-Natal, South Africa. However, the proportion of PLWH entering care with AHD remains consistently high, affecting 1 in 4 PLWH accessing HIV services. In addition, there is an increasing number of ART-experienced patients with AHD. Implementation of male-friendly services, combined with intensified adherence support and re-engagement initiatives should be considered to reduce mortality risk for PLWH in rural regions in South Africa.
- 18 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0317674
Open AccessPersistent advanced HIV disease in rural KwaZulu-Natal, South Africa: Trends, characteristics, and the urgent need for targeted interventions
Background: Advanced HIV disease (AHD) remains a persistent public health challenge. Data regarding the burden, characteristics and predictors of AHD is scarce specifically for rural settings of sub-Saharan Africa. This study aimed to describe trends in annual CD4 count distribution and to characterise adult persons living with HIV (PLWH) on ART who have AHD in rural KwaZulu-Natal, South Africa. Methods: A retrospective cohort design of annual CD4 count distribution was conducted among antiretroviral therapy (ART) patients aged 18 years and older. We used routinely collected data from adults receiving ART in Eshowe and Mbongolwane areas in KwaZulu-Natal, South Africa, between January 1, 2008, and June 30, 2021. Fine-Greys competing risks regression with proportional sub-distribution hazard models was used to determine factors associated with time to CD4 recovery. Results: A total of 34,729 patients were included of which 68.5% were females. The median age of the study sample was 33.5 years (interquartile range [IQR] 27–41 years), and the median CD4 count was 277 cells/μL (IQR, 149–452 cells/μL). The proportion of patients entering care with AHD declined over time from 62% in 2008 to 20% in 2021. Across all periods, those entering care with AHD were more likely to be men when compared to women (Relative risk [RR] 1.49; 95% 1.33–1.67). In addition, the proportion of patients with AHD who were ART-experienced increased from 4% in 2008 to 63% in 2021. Among ART-experienced, men were more likely to present with AHD compared to women (RR 1.79; 95% CI 1.52–2.11). Among those with AHD, the cumulative incidence of CD4 recovery to > 350 cells/μL was 3.21 (95% CI 3.13–3.29) per 100 adult-years follow-up time. Conclusion: Over time fewer patients with AHD are entering care in KwaZulu-Natal, South Africa. However, the proportion of PLWH entering care with AHD remains consistently high, affecting 1 in 4 PLWH accessing HIV services. In addition, there is an increasing number of ART-experienced patients with AHD. Implementation of male-friendly services, combined with intensified adherence support and re-engagement initiatives should be considered to reduce mortality risk for PLWH in rural regions in South Africa.
- Open Access
- 22 August 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-16
Prevalence and trends of advanced HIV disease among antiretroviral therapy-naïve and antiretroviral therapy-experienced patients in South Africa between 2010-2021: a systematic review and meta-analysis
Background: Despite the significant progress made in South Africa in getting millions of individuals living with HIV into care, many patients still present or re-enter care with Advanced HIV Disease (AHD). We aimed to estimate the prevalence of AHD among ART-naive and ART-experienced patients in South Africa using studies published between January 2010 and May 2022. Methods: We searched for relevant data on PubMed, CINAHL, Scopus and other sources, with a geographical filters limited to South Africa, up to May 31, 2022. Two reviewers conducted all screening, eligibility assessment, data extraction, and critical appraisal. We synthesized the data using the inverse-variance heterogeneity model and Freeman-Tukey transformation. We assessed heterogeneity using the I2 statistic and publication bias using the Egger and Begg’s test. Results: We identified 2,496 records, of which 53 met the eligibility criteria, involving 11,545,460 individuals. The pooled prevalence of AHD among ART-naive and ART-experienced patients was 43.45% (95% CI 40.1–46.8%, n = 53 studies) and 58.6% (95% CI 55.7 to 61.5%, n = 2) respectively. The time trend analysis showed a decline of 2% in the prevalence of AHD among ART-naive patients per year. However, given the high heterogeneity between studies, the pooled prevalence should be interpreted with caution. Conclusion: Despite HIV’s evolution to a chronic disease, our findings show that the burden of AHD remains high among both ART-naive and ART-experienced patients in South Africa. This emphasizes the importance of regular measurement of CD4 cell count as an essential component of HIV care. In addition, providing innovative adherence support and interventions to retain ART patients in effective care is a crucial priority for those on ART.
- 22 August 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-16
Open AccessPrevalence and trends of advanced HIV disease among antiretroviral therapy-naïve and antiretroviral therapy-experienced patients in South Africa between 2010-2021: a systematic review and meta-analysis
Background: Despite the significant progress made in South Africa in getting millions of individuals living with HIV into care, many patients still present or re-enter care with Advanced HIV Disease (AHD). We aimed to estimate the prevalence of AHD among ART-naive and ART-experienced patients in South Africa using studies published between January 2010 and May 2022. Methods: We searched for relevant data on PubMed, CINAHL, Scopus and other sources, with a geographical filters limited to South Africa, up to May 31, 2022. Two reviewers conducted all screening, eligibility assessment, data extraction, and critical appraisal. We synthesized the data using the inverse-variance heterogeneity model and Freeman-Tukey transformation. We assessed heterogeneity using the I2 statistic and publication bias using the Egger and Begg’s test. Results: We identified 2,496 records, of which 53 met the eligibility criteria, involving 11,545,460 individuals. The pooled prevalence of AHD among ART-naive and ART-experienced patients was 43.45% (95% CI 40.1–46.8%, n = 53 studies) and 58.6% (95% CI 55.7 to 61.5%, n = 2) respectively. The time trend analysis showed a decline of 2% in the prevalence of AHD among ART-naive patients per year. However, given the high heterogeneity between studies, the pooled prevalence should be interpreted with caution. Conclusion: Despite HIV’s evolution to a chronic disease, our findings show that the burden of AHD remains high among both ART-naive and ART-experienced patients in South Africa. This emphasizes the importance of regular measurement of CD4 cell count as an essential component of HIV care. In addition, providing innovative adherence support and interventions to retain ART patients in effective care is a crucial priority for those on ART.
- Open Access
- 13 March 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (3) , e0000493
Economic evaluation of a cluster randomized, non-inferiority trial of differentiated service delivery models of HIV treatment in Zimbabwe
About 85% of Zimbabwe’s >1.4 million people living with HIV are on antiretroviral treatment (ART). Further expansion of its treatment program will require more efficient use of existing resources. Two promising strategies for reducing resource utilization per patient are multi-month medication dispensing and community-based service delivery. We evaluated the costs to providers and patients of community-based, multi-month ART delivery models in Zimbabwe. We used resource and outcome data from a cluster-randomized non-inferiority trial of three differentiated service delivery (DSD) models targeted to patients stable on ART: 3-month facility-based care (3MF), community ART refill groups (CAGs) with 3-month dispensing (3MC), and CAGs with 6-month dispensing (6MC). Using local unit costs, we estimated the annual cost in 2020 USD of providing HIV treatment per patient from the provider and patient perspectives. In the trial, retention at 12 months was 93.0% in the 3MF, 94.8% in the 3MC, and 95.5% in the 6MC arms. The total average annual cost of HIV treatment per patient was $187 (standard deviation $39), $178 ($30), and $167 ($39) in each of the three arms, respectively. The annual cost/patient was dominated by ART medications (79% in 3MF, 87% in 3MC; 92% in 6MC), followed by facility visits (12%, 5%, 5%, respectively) and viral load (8%, 8%, 2%, respectively). When costs were stratified by district, DSD models cost slightly less, with 6MC the least expensive in all districts. Savings were driven by differences in the number of facility visits made/year, as expected, and low uptake of annual viral load tests in the 6-month arm. The total annual cost to patients to obtain HIV care was $10.03 ($2) in the 3MF arm, $5.12 ($0.41) in the 3MC arm, and $4.40 ($0.39) in the 6MF arm. For stable ART patients in Zimbabwe, 3- and 6-month community-based multi-month dispensing models cost less for both providers and patients than 3-month facility-based care and had non-inferior outcomes.
- 13 March 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (3) , e0000493
Open AccessEconomic evaluation of a cluster randomized, non-inferiority trial of differentiated service delivery models of HIV treatment in Zimbabwe
About 85% of Zimbabwe’s >1.4 million people living with HIV are on antiretroviral treatment (ART). Further expansion of its treatment program will require more efficient use of existing resources. Two promising strategies for reducing resource utilization per patient are multi-month medication dispensing and community-based service delivery. We evaluated the costs to providers and patients of community-based, multi-month ART delivery models in Zimbabwe. We used resource and outcome data from a cluster-randomized non-inferiority trial of three differentiated service delivery (DSD) models targeted to patients stable on ART: 3-month facility-based care (3MF), community ART refill groups (CAGs) with 3-month dispensing (3MC), and CAGs with 6-month dispensing (6MC). Using local unit costs, we estimated the annual cost in 2020 USD of providing HIV treatment per patient from the provider and patient perspectives. In the trial, retention at 12 months was 93.0% in the 3MF, 94.8% in the 3MC, and 95.5% in the 6MC arms. The total average annual cost of HIV treatment per patient was $187 (standard deviation $39), $178 ($30), and $167 ($39) in each of the three arms, respectively. The annual cost/patient was dominated by ART medications (79% in 3MF, 87% in 3MC; 92% in 6MC), followed by facility visits (12%, 5%, 5%, respectively) and viral load (8%, 8%, 2%, respectively). When costs were stratified by district, DSD models cost slightly less, with 6MC the least expensive in all districts. Savings were driven by differences in the number of facility visits made/year, as expected, and low uptake of annual viral load tests in the 6-month arm. The total annual cost to patients to obtain HIV care was $10.03 ($2) in the 3MF arm, $5.12 ($0.41) in the 3MC arm, and $4.40 ($0.39) in the 6MF arm. For stable ART patients in Zimbabwe, 3- and 6-month community-based multi-month dispensing models cost less for both providers and patients than 3-month facility-based care and had non-inferior outcomes.
- Open Access
- 1 November 2022
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 112 (11) , 838
Factors associated with success at COVID- 19 vaccination sites in South Africa
[1] recently reported lessons learnt for COVID-19 vaccination scale-up in South Africa (SA) from the Sisonke vaccine implementation study for healthcare workers. Despite this important study, SA did not achieve its target of providing COVID-19 vaccination for 67% of the population by December 2021. Furthermore, during 2022, vaccination rates have decreased substantially, with only 46% and 12% of SA adults and children aged 12-17 years being fully vaccinated, respectively (as at August 2022). [2] Vaccine hesitancy in the country is an important issue, with a substantial proportion of vulnerable people being unsure of or unwilling to receive COVID-19 vaccination. [3,4] Achieving high population vaccination coverage is further challenged by approximately one-third of the population being aged 280 000 COVID-19 vaccinations utilising donor funding, in partnership with the Department of Health (DoH), in 11 districts in the Eastern Cape, Western Cape and KwaZulu-Natal provinces between September 2021 and June 2022. Forty-six vaccination teams were in the programme, which included small mobile teams that serviced rural areas and schools. Six key factors emerged as important determinants of how successful a site/ team was in reaching high daily numbers of individuals vaccinated. 1. Active support and buy-in from the DoH: This emerged as a key enabler. Cooperative involvement in and close coordination of activities by the DoH (including managers of local hospitals) substantially improved vaccine team efficiency. Where DoH support was fragmented and not well coordinated , motivation and morale of vaccine team staff suffered. 2. Demand creation: Closely linked with vaccination activities, this was vital to increase numbers vaccinated. Vaccination staff needed to be immediately ready to provide vaccinations following demand creation, and needed to work together with demand creators. Demand creation activities included using loudhailers , going door-to-door, education at clinics and scheduling times at schools for vaccine education. Demand creation using social media was viewed as being important to reach adolescents going forward, including to address vaccine hesitancy.
- 1 November 2022
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 112 (11) , 838
Open AccessFactors associated with success at COVID- 19 vaccination sites in South Africa
[1] recently reported lessons learnt for COVID-19 vaccination scale-up in South Africa (SA) from the Sisonke vaccine implementation study for healthcare workers. Despite this important study, SA did not achieve its target of providing COVID-19 vaccination for 67% of the population by December 2021. Furthermore, during 2022, vaccination rates have decreased substantially, with only 46% and 12% of SA adults and children aged 12-17 years being fully vaccinated, respectively (as at August 2022). [2] Vaccine hesitancy in the country is an important issue, with a substantial proportion of vulnerable people being unsure of or unwilling to receive COVID-19 vaccination. [3,4] Achieving high population vaccination coverage is further challenged by approximately one-third of the population being aged 280 000 COVID-19 vaccinations utilising donor funding, in partnership with the Department of Health (DoH), in 11 districts in the Eastern Cape, Western Cape and KwaZulu-Natal provinces between September 2021 and June 2022. Forty-six vaccination teams were in the programme, which included small mobile teams that serviced rural areas and schools. Six key factors emerged as important determinants of how successful a site/ team was in reaching high daily numbers of individuals vaccinated. 1. Active support and buy-in from the DoH: This emerged as a key enabler. Cooperative involvement in and close coordination of activities by the DoH (including managers of local hospitals) substantially improved vaccine team efficiency. Where DoH support was fragmented and not well coordinated , motivation and morale of vaccine team staff suffered. 2. Demand creation: Closely linked with vaccination activities, this was vital to increase numbers vaccinated. Vaccination staff needed to be immediately ready to provide vaccinations following demand creation, and needed to work together with demand creators. Demand creation activities included using loudhailers , going door-to-door, education at clinics and scheduling times at schools for vaccine education. Demand creation using social media was viewed as being important to reach adolescents going forward, including to address vaccine hesitancy.
- Open Access
- 6 May 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 1200
Thank Martin Luther that ciprofloxacin could cure your gonorrhoea? Ecological association between Protestantism and antimicrobial consumption in 30 European countries
Background:Higher consumption of antimicrobials plays an important role in driving the higher prevalence of antimicrobial resistance in Southern compared to Northern Europe. Poor controls on corruption (CoC), high uncertainty avoidance (UA) and performance vs. cooperation orientation (POCO) of societies have been found to explain much of this higher consumption in Southern European countries. We hypothesized that these predictors were in turn influenced by the Protestant Reformation in the 16thcentury onwards. Methods:We used structural equation modelling (SEM) to assess the relationships between country-level proportions being Protestant, CoC, UA, POCO and four markers of antimicrobial consumption in the community (all antibacterials, cephalosporin, macrolides and fluoroquinolones). Results:The proportion of a country that was Protestant was negatively correlated with the consumption of all antibacterials. SEM revealed that UA predicted all antibacterial consumption (direct effect coef. 0.15, 95% Confidence Interval [CI] 0.04-0.26). The proportion Protestant exerted an indirect effect on consumption (coef. -0.13, 95% CI -0.21- -0.05). This effect was mediated predominantly via its effect on UA (direct effect coef. 0.15, 95% CI 0.04-0.26). The model explained 37% of the variation in consumption. Similar results were obtained for each of the other three classes of antimicrobials investigated. Conclusions:Our results are compatible with the theory that contemporary differences in antimicrobial consumption in Europe stem in part from cultural differences that emerged in the Reformation. These findings may explain the differential efficacy of similar antibiotic stewardship campaigns in Northern and Southern European populations.
- 6 May 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 1200
Open AccessThank Martin Luther that ciprofloxacin could cure your gonorrhoea? Ecological association between Protestantism and antimicrobial consumption in 30 European countries
Background:Higher consumption of antimicrobials plays an important role in driving the higher prevalence of antimicrobial resistance in Southern compared to Northern Europe. Poor controls on corruption (CoC), high uncertainty avoidance (UA) and performance vs. cooperation orientation (POCO) of societies have been found to explain much of this higher consumption in Southern European countries. We hypothesized that these predictors were in turn influenced by the Protestant Reformation in the 16thcentury onwards. Methods:We used structural equation modelling (SEM) to assess the relationships between country-level proportions being Protestant, CoC, UA, POCO and four markers of antimicrobial consumption in the community (all antibacterials, cephalosporin, macrolides and fluoroquinolones). Results:The proportion of a country that was Protestant was negatively correlated with the consumption of all antibacterials. SEM revealed that UA predicted all antibacterial consumption (direct effect coef. 0.15, 95% Confidence Interval [CI] 0.04-0.26). The proportion Protestant exerted an indirect effect on consumption (coef. -0.13, 95% CI -0.21- -0.05). This effect was mediated predominantly via its effect on UA (direct effect coef. 0.15, 95% CI 0.04-0.26). The model explained 37% of the variation in consumption. Similar results were obtained for each of the other three classes of antimicrobials investigated. Conclusions:Our results are compatible with the theory that contemporary differences in antimicrobial consumption in Europe stem in part from cultural differences that emerged in the Reformation. These findings may explain the differential efficacy of similar antibiotic stewardship campaigns in Northern and Southern European populations.